Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
HSTRF Hollister Biosciences Inc
T AT&T Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
MSFT Microsoft Corp
PEY Invesco High Yield Equity Dividend Achievers™ ETF
BAC Bank of America Corp
ARI Apollo Commercial Real Estate Finance Inc
ISNPY Intesa Sanpaolo SpA
BRKR Bruker Corp
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Closing Price
$163.55
Day's Change
1.82 (1.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
165.16
Day's Low
161.87
Volume
(Average)
Volume:
8,137,018

10-day average volume:
7,778,285
8,137,018

Display:

Providers:

UpdateCancel
4 providers
Today's News, January 24, 2021
UPDATE: Tech's 'last hurrah'? If hedge funds are any indication, it could be a big week for Apple, Amazon and other megacap favorites

Shawn Langlois That's Gene Goldman, chief investment officer at Cetera Financial Group, talking to Bloomberg News (https://www.bloomberg.com/news/articles/2021-01-23/hedge-funds-beef-up-tech-holdings-before-apple-amazon-earnings)about a...(MarketWatch)

Tech's 'last hurrah?' If hedge funds are any indication, it could be a big week for Apple, Amazon and other prominent megacaps

Shawn Langlois That's Gene Goldman, chief investment officer at Cetera Financial Group, talking to Bloomberg News (https://www.bloomberg.com/news/articles/2021-01-23/hedge-funds-beef-up-tech-holdings-before-apple-amazon-earnings)about a...(MarketWatch)

January 20, 2021
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $162.38, marking a -0.25% move from the previous day.(Zacks)

Johnson & Johnson stock price target raised to $170 from $160 at UBS

(END) Dow Jones Newswires January 20, 2021 09:16 ET (14:16 GMT) (MarketWatch)

January 18, 2021
Fauci says two more COVID-19 vaccines could be approved within 'weeks'

By The New York Post Dr. Anthony Fauci on Sunday that Johnson & Johnson and AstraZeneca could send studies of their COVID-19 vaccines to the feds for approval within "weeks." (MarketWatch)

UPDATE: Fauci says two more COVID-19 vaccines could be approved within 'weeks'

By The New York Post Dr. Anthony Fauci on Sunday that Johnson & Johnson and AstraZeneca could send studies of their COVID-19 vaccines to the feds for approval within "weeks." (MarketWatch)

January 14, 2021
J&J's COVID-19 vaccine candidate shows it generates antibodies in early-stage trial

Shares of Johnson & Johnson (JNJ) gained 1.7% in premarket trading on Thursday, the day after a study (https://www.nejm.org/doi/full/10.1056/NEJMoa2034201%7CNEW) published in the New England Journal of Medicine showed that its COVID-19...(MarketWatch)

January 13, 2021
Johnson & Johnson vaccine production is behind schedule: report

Federal officials have been told that Johnson & Johnson's (JNJ) vaccine production has fallen as much as two months behind the original production schedule and won't catch up until the end of April, The New York Times reported...(MarketWatch)

January 11, 2021
UPDATE: Dow snaps 4-day win streak as investors focus on hopes for recovery, political transition

By Joy Wiltermuth and Sunny Oh Rising Treasury yields also in focus Stock indexes booked modest losses Monday, backing off from Friday's records, as investors remained optimistic about the prospects for the incoming Biden...(MarketWatch)

January 07, 2021
UPDATE: Third vaccine could be authorized for U.K. within weeks, boosting mass immunization drive, top scientist says

By Lina Saigol The U.K government wants to have 13 million of those people most at risk vaccinated by mid February The COVID-19 vaccine candidate being developed by Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceutica could be...(MarketWatch)

Third vaccine could be approved for U.K. within weeks boosting mass immunisation drive, top scientist says

By Lina Saigol The U.K government wants to have 13 million of those people most at risk vaccinated by mid February The COVID-19 vaccine candidate being developed by Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceutica could be...(MarketWatch)

January 02, 2021
UPDATE: These are the best-performing Nasdaq and S&P 500 stocks of 2020

Coca-Cola Co. US:KO -1% 3M Co. US:MMM -1% American Express Co. US:AXP -3% Verizon Communications Inc...(MarketWatch)

December 17, 2020
UPDATE: New COVID-19 vaccine candidate Valneva starts clinical trials

By Lina Saigol Valneva's is the fifth COVID-19 vaccine candidate in the U.K., but scientists have warned that it could take at least a year to inoculate the entire population (MarketWatch)

December 16, 2020
UPDATE: COVID-19 hospitalizations rise to a 10th-straight daily record, as nearly 3,000 die in the past day

Tomi Kilgore U.S. death count passes 304,000 and as hospitalizations near 113,000 Nearly 3,000 people died from COVID-19 in the past day and hospitalizations rose to just below 113,000, to mark a 10th-straight daily record, just days...(MarketWatch)

COVID-19 hospitalizations rise to a 10th-straight daily record, as nearly 3,000 die in the past day

Tomi Kilgore U.S. death count passes 304,000 and as hospitalizations near 113,000 Nearly 3,000 people died from COVID-19 in the past day and hospitalizations rose to just below 113,000, to mark a 10th-straight daily record, just days...(MarketWatch)

December 08, 2020
UPDATE: This is why I volunteered for the Novavax COVID-19 vaccine trial, and am still cheering for the underdog

Pierre Briançon 'No, I never considered it was risky, and no, of course, I'm not getting paid. I just received my second shot a few days ago,' writes Pierre Briançon of volunteering for a vaccine trial in London (MarketWatch)

December 02, 2020
UPDATE: This is why I volunteered for the Novavax COVID-19 vaccine trial, and am still cheering for the underdog

Pierre Briançon 'No, I never considered it was risky, and no, of course, I'm not getting paid. I just received my second shot a few days ago,' writes Pierre Briançon of volunteering for a vaccine trial in London (MarketWatch)

November 26, 2020
I've already been injected with a COVID vaccine. This is why I'm cheering for the Novavax underdog

Pierre Briançon "No, I never considered it was risky, and no, of course, I'm not getting paid. I just received my second shot a few days ago. " The first question that came to my friends' minds was whether I'd really thought about the...(MarketWatch)

November 24, 2020
UPDATE: EU strikes deal with Moderna to supply up to 160 million COVID vaccine shots

By Lina Saigol The European Union has now negotiated six supply deals with vaccine makers to secure COVID-19 shots The European Union has struck a deal with U.S. biotech Moderna (MRNA) for the supply of up to 160 million doses of its...(MarketWatch)

EU strikes deal with Moderna to supply up to 160 million vaccine shots

By Lina Saigol The European Union has struck a deal with U.S. biotech Moderna (MRNA) for the supply of up to 160 million doses of its experimental COVID-19 vaccine, the head of the European Commission said on Tuesday. (MarketWatch)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.